

2018 Current Fiscal Year Report: Office of AIDS Research Advisory Council

Report Run Date: 06/05/2019 12:18:54 PM

1. Department or Agency

Department of Health and Human Services

2. Fiscal Year

2018

3. Committee or Subcommittee

Office of AIDS Research Advisory Council

3b. GSA Committee No.

1918

4. Is this New During Fiscal Year?

No

5. Current Charter

06/27/2018

6. Expected Renewal Date

06/27/2020

7. Expected Term Date

8a. Was Terminated During Fiscal Year?

No

8b. Specific Termination Authority

8c. Actual Term Date

9. Agency Recommendation for Next Fiscal Year

Continue

10a. Legislation Req to Terminate?

Not Applicable

10b. Legislation Pending?

Not Applicable

11. Establishment Authority

Statutory (Congress Created)

12. Specific Establishment Authority

42 USC 300cc-40a

13. Effective Date

06/10/1993

14. Committee Type

Continuing

14c. Presidential?

No

15. Description of Committee

Scientific Technical Program Advisory Board

16a. Total Number of Reports

No Reports for this Fiscal Year

17a. Open Meetings and Dates 2 17b. Closed Meetings and Dates 0 17c. Partially Closed Meetings and Dates 1 17d. Total Meetings and Dates 3

Purpose

Program Advisory

Start

11/16/2017

End

- 11/16/2017

Program Advisory

03/27/2018

- 03/27/2018

Program Advisory

07/12/2018

- 07/12/2018

Number of Committee Meetings Listed: 3

	Current FY	Next FY
18a(1). Personnel Pmts to Non-Federal Members	\$10,400.00	\$10,400.00
18a(2). Personnel Pmts to Federal Members	\$0.00	\$0.00
18a(3). Personnel Pmts to Federal Staff	\$187,630.00	\$147,885.00
18a(4). Personnel Pmts to Non-Member Consultants	\$0.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$34,499.00	\$34,704.00
18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.00	\$0.00
18c. Other(rents,user charges, graphics, printing, mail, etc.)	\$16,378.00	\$16,542.00

18d. Total	\$248,907.00	\$209,531.00
19. Federal Staff Support Years (FTE)	1.40	1.10

20a. How does the Committee accomplish its purpose?

The Office of AIDS Research Advisory Council (OARAC) is composed of highly qualified individuals who possess scientific expertise in AIDS research and a public commitment to advance the AIDS scientific agenda. The Council provides a breadth and balance of specialized knowledge necessary to advise the Director of the Office of AIDS Research (OAR) and the Director of the National Institutes of Health (NIH). The NIH Revitalization Act of 1993 called for the establishment of OARAC to provide advice on planning, coordination, and evaluating AIDS research supported by the NIH and to advise on the awarding of funds from the OAR Discretionary Fund. The OAR depends heavily on the Council's advice in the extensive process of reviewing all NIH AIDS research and developing long-term research plans. To accomplish this, briefing sessions on specific topics that are timely and of relevance were presented during FY 2018 to update the OARAC on: Status of NIAID plans for the DAIDS-sponsored clinical trials networks, due to be re-competed in FY 2019; Status of plans for the MACS and WIHS prospective cohort studies which beginning in FY 2019 the NHLBI will manage awards for as a combined cohort study to focus research priorities on chronic HIV-related comorbidities; Update from NIDA on the domestic opioid crisis and HIV; Updates from OAR staff on trans-NIH cost sharing for funding areas of science that have both HIV/AIDS and non-AIDS-related components; Updates on OAR development of a two-year trans-NIH plan for HIV-related research for FY 2019-20, and plans for multi-year plans after that transitional year (up until now, trans-NIH plans have been prepared annually); Status of the reorganization of AIDS and Related Research (AARR) integrated review group study sections by the CSR; Updates on HIV-related research portfolios of several NIH Institutes, Centers and NIH/OD Offices (NCI, NIA, NICHD, NIMH and OD/ORIP); The Council also advised on the activities of the five HHS HIV/AIDS Treatment Guideline panels of experts in HIV care who, constituted as Working Groups of the OARAC, maintain updated federally approved medical practice guidelines for HIV/AIDS care and treatment.

20b. How does the Committee balance its membership?

The OARAC is composed of eighteen authorized members, twelve of whom are authorities in the fields of molecular biology, immunology, virology, neurology, pediatrics, vaccine development, antiviral development, clinical care, animal model research, retrovirology, structural biology, infectious disease, epidemiology, mental health, and substance abuse/addictions sciences. Six public members have expertise in public policy, health policy, economics, and management.

20c. How frequent and relevant are the Committee Meetings?

The OARAC meets approximately three times a year and provides advice on a continuing basis on the direction of the NIH AIDS research program, the development and annual review of a comprehensive plan for the conduct and support of all AIDS activities of the agencies of NIH, including direct involvement in budget projections for carrying out the plan which includes an estimate of the number and type of personnel needed for OAR. The Committee conducted three meetings on the following dates: 11/16/2017, 03/27/2018 and 07/12/2018.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

The committee and membership requirements are specifically addressed in statute. AIDS research is conducted throughout the NIH, which includes 23 institutes and Centers, and 3 NIH OD Offices. The OARAC is the only council with advisory responsibilities applicable to the entire NIH AIDS research program. Therefore, it is essential to the coordination of the NIH AIDS scientific effort and research direction of the agency's AIDS programs.

20e. Why is it necessary to close and/or partially closed committee meetings?

The November 16, 2017 OARAC meeting was partially closed in accordance with section 10(d) of the Federal Advisory Committee Act (FACA) and provisions set forth in sections 552b(c)(6) and 552b(c)(9)(B), Title 5 U.S.C. The proposed closed portion of the meeting included the review, discussion, and Council amendment or approval of the recommendations from the Working Groups of the OARAC that update the HHS Treatment and Prevention Guidelines for medical care of people living with HIV in the United States. The premature disclosure of information which would be likely to significantly frustrate implementation of a proposed agency action.

21. Remarks

There were no formal, substantive committee reports made to the Agency, the President, or the Congress in FY 2018. Members Agosto-Rosario, Diclemente, Gandhi and Kuritzkes were administratively extended until 3/30/2018. Dr. Raab-Traub was assigned as the National Cancer Advisory Board representative to OARAC as required by the Charter. In FY 18, Dr. Goodenow, in the DFO capacity, was replaced by Dr. Jay R. Radke, Supervisory Health Science Administrator. Mary Jane Rotheram-Borus, Ex-officio, was removed by the Exec Sec in FY17 and is no longer on the Council.

Designated Federal Officer

Jay R. Radke Supervisory Health Science Administrator

Committee Members Start

End

Occupation

Member Designation

AGOSTO-ROSARIO, MOISES	11/13/2014	03/30/2018	DIRECTOR OF TREATMENT	Special Government Employee (SGE) Member
AKE, JULIE	06/01/2017	09/30/2020	PRINCIPAL DEPUTY DIRECTOR	Ex Officio Member
ANDERSON, JAMES	08/17/2015	09/30/2019	Director, Division of Program Coordination, Planning and Strategic Initiatives, NIH	Ex Officio Member
Azar, Alex	01/29/2018	01/20/2021	Secretary, HHS	Ex Officio Member
CELENTANO, DAVID	09/19/2017	09/30/2018	PROFESSOR	Special Government Employee (SGE) Member
CHIN, JOHN	05/23/2017	09/30/2020	ASSOCIATE PROFESSOR	Special Government Employee (SGE) Member
COLLINS, FRANCIS	08/16/2009	01/20/2021	DIRECTOR	Ex Officio Member
Connick, Elizabeth	11/15/2017	09/30/2018	PROFESSOR	Special Government Employee (SGE) Member
DAVEY, VICTORIA	08/17/2015	09/30/2019	Chief Officer, U.S. Department of Veterans Affairs	Ex Officio Member
DICLEMENTE, RALPH	04/15/2015	03/30/2018	CHARLES HOWARD CANDLER PROF OF PUBLIC HEALTH	Special Government Employee (SGE) Member
DIEFFENBACH, CARL	08/17/2015	09/30/2019	DIRECTOR	Ex Officio Member
DIXON-DIALLO, DAZON	11/15/2017	09/30/2019	PRESIDENT/CHIEF EXECUTIVE OFFICER	Special Government Employee (SGE) Member
GANDHI, MONICA	02/08/2015	03/30/2018	PROFESSOR	Special Government Employee (SGE) Member
Goodenow, Maureen	10/01/2016	09/30/2018	DIRECTOR, OFFICE OF AIDS RESEARCH	Ex Officio Member
Hargan, Eric	10/10/2017	01/29/2018	Acting Secretary, HHS	Ex Officio Member
KATES, JENNIFER	08/19/2017	09/30/2020	VICE PRESIDENT AND DIRECTOR, GLOBAL HEALTH AND HIV POLICY	Special Government Employee (SGE) Member
KURITZKES, DANIEL	04/01/2015	03/30/2018	CHIEF	Special Government Employee (SGE) Member
MERMIN, JONATHAN	08/17/2015	09/30/2019	Director, National Center for HIV/AIDS, The Centers for Disease Control	Ex Officio Member
MICHAEL, NELSON	08/17/2015	09/30/2019	Colonel, Medical Corps, Military HIV Research Program	Ex Officio Member
MOFENSON, LYNNE	10/14/2016	09/30/2019	HIV SENIOR TECHNICAL ADVISOR	Special Government Employee (SGE) Member
RHODES, SCOTT	09/21/2016	09/30/2019	PROFESSOR	Special Government Employee (SGE) Member
WIRA, CHARLES	05/23/2017	09/30/2019	PROFESSOR	Special Government Employee (SGE) Member
Wright, Don	09/29/2017	10/10/2017	Acting Secretary, HHS	Ex Officio Member

Number of Committee Members Listed: 23

Narrative Description

The goal of NIH research is to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability, from the rarest genetic disorder to the common cold. The NIH mission is to uncover new knowledge that will lead to better health for everyone. All of the NIH Institutes and Centers sponsor AIDS research. The OARAC is the only council with advisory responsibilities applicable to the entire NIH AIDS research program.

Therefore, it is essential to the coordination of the NIH AIDS scientific effort and research direction of the agency's AIDS programs. At each meeting, the OARAC receives an update on the activities of the five Working Groups. These Working Groups are sponsored under the auspices of the OARAC and are responsible for the development of

state-of-the-science federal guidelines for the medical management of HIV disease and its associated coinfections and opportunistic infections in adults, adolescents, and children.

What are the most significant program outcomes associated with this committee?

Checked if Applies

- | | |
|---|-------------------------------------|
| Improvements to health or safety | <input checked="" type="checkbox"/> |
| Trust in government | <input type="checkbox"/> |
| Major policy changes | <input checked="" type="checkbox"/> |
| Advance in scientific research | <input checked="" type="checkbox"/> |
| Effective grant making | <input checked="" type="checkbox"/> |
| Improved service delivery | <input type="checkbox"/> |
| Increased customer satisfaction | <input type="checkbox"/> |
| Implementation of laws or regulatory requirements | <input type="checkbox"/> |
| Other | <input type="checkbox"/> |

Outcome Comments

NA

What are the cost savings associated with this committee?

Checked if Applies

- | | |
|----------------------------|-------------------------------------|
| None | <input checked="" type="checkbox"/> |
| Unable to Determine | <input type="checkbox"/> |
| Under \$100,000 | <input type="checkbox"/> |
| \$100,000 - \$500,000 | <input type="checkbox"/> |
| \$500,001 - \$1,000,000 | <input type="checkbox"/> |
| \$1,000,001 - \$5,000,000 | <input type="checkbox"/> |
| \$5,000,001 - \$10,000,000 | <input type="checkbox"/> |
| Over \$10,000,000 | <input type="checkbox"/> |
| Cost Savings Other | <input type="checkbox"/> |

Cost Savings Comments

NIH supported basic and clinical research accomplishments which often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

140

Number of Recommendations Comments

Briefing sessions on specific topics that are timely and of relevance were presented during FY2018 to update the OARAC on: Update from NIDA on the domestic opioid crisis and HIV; Updates from OAR staff on trans-NIH cost sharing for funding areas of science that have both HIV/AIDS and non-AIDS-related components; Updates on OAR development of a two-year trans-NIH plan for HIV-related research for FY2019-20, and plans for multi-year plans after that transitional year (up until now, trans-NIH plans have been prepared annually); Status of the reorganization of AIDS and Related Research (AARR) integrated review group study sections by the CSR; Updates on HIV-related research portfolios of several NIH Institutes, Centers and NIH/OD Offices (NCI, NIA, NICHD, NIMH and OD/ORIP). The Council also advised on the activities of the five HHS HIV/AIDS Treatment Guideline panels of experts in HIV care who, constituted as Working Groups of the OARAC, maintain updated federally approved medical practice guidelines for HIV/AIDS care and treatment.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

0%

% of Recommendations Fully Implemented Comments

Due to the complexity of the recommendations made by this committee, staff is unable to determine which recommendations have been fully or partially implemented solely in response to this committee's activities.

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

0%

% of Recommendations Partially Implemented Comments

Due to the complexity of the recommendations made by this committee, staff is unable to determine which recommendations have been fully or partially implemented solely in response to this committee's activities.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes ☒ No ☐ Not Applicable ☐

Agency Feedback Comments

Minutes, oral presentations, and written reports.

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

- | | |
|-----------------------------------|-------------------------------------|
| Reorganized Priorities | <input type="checkbox"/> |
| Reallocated resources | <input type="checkbox"/> |
| Issued new regulation | <input type="checkbox"/> |
| Proposed legislation | <input type="checkbox"/> |
| Approved grants or other payments | <input type="checkbox"/> |
| Other | <input checked="" type="checkbox"/> |

Action Comments

The Committee makes recommendations to the federal staff on the planning, coordination, and evaluation of research and other activities in respect to AIDS conducted or supported by the NIH. OARAC also advises the Secretary of Health and Human Services, the Assistant Secretary for Health, the Director of NIH, and the Director of OAR, on AIDS research programs, the development and annual review of the comprehensive plan for the conduct and support of all AIDS activities of the agencies of NIH, including research policies and priorities, and the coordination of domestic and international NIH AIDS efforts.

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

NA

How is access provided to the information for the Committee's documentation?

Checked if Applies

- | | |
|---------------------------|-------------------------------------|
| Contact DFO | <input checked="" type="checkbox"/> |
| Online Agency Web Site | <input checked="" type="checkbox"/> |
| Online Committee Web Site | <input checked="" type="checkbox"/> |
| Online GSA FACA Web Site | <input checked="" type="checkbox"/> |
| Publications | <input type="checkbox"/> |
| Other | <input type="checkbox"/> |

Access Comments

N/A